Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aprea Therapeutics, Inc.APRE · Entity 7948 | SVP, Chief Operating Officer | July 28, 2022 | August 01, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aprea Therapeutics, Inc.
Report date July 28, 2022 · Filed August 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,762 |
Reported balance
After 2022-07-28 transaction · row 1
1 source rowRow 1 · 2022-07-28 · Grant · Acquired 24,300 · Balance 45,762 F1: These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock as follows: (i) 8,100 shares on July 28, 2023, (ii) 8,100 shares on July 28, 2024 and (iii) 8,100 shares on July 28, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2032-07-28 | Direct | 35,700 |
Reported balance
After 2022-07-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-07-28 · Grant · Acquired 35,700 · Balance 35,700 F2: Twenty-five percent of these options vest on July 28, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock as follows: (i) 8,100 shares on July 28, 2023, (ii) 8,100 shares on July 28, 2024 and (iii) 8,100 shares on July 28, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2: Twenty-five percent of these options vest on July 28, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2022 Filed Aug 1, 2022 21:04 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 35,700 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001104659-22-084767 · tm2222147-6_4seq1.xml · derivative · entry 2 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,700 Underlying: Common Stock · 35,700 shares Expires 2032-07-28 F2 · derivative.exercise_date: Twenty-five percent of these options vest on July 28, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 21:04 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 24,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-084767 · tm2222147-6_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,762 F1 · shares: These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock as follows: (i) 8,100 shares on July 28, 2023, (ii) 8,100 shares on July 28, 2024 and (iii) 8,100 shares on July 28, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Tax withholdingCommon Stock | 8,390 | $0.81 | $6,753.95 |
DisclosureSEC source: 0001104659-22-069001 · tm2217848-2_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · Director · SVP, Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,462 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 24,334 restricted stock units Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:03 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 72,600 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001104659-22-033392 · tm229119-4_4seq1.xml · derivative · entry 3 Korbel Gregory Alan · CIK 0001789032 · Director · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,600 Underlying: Common Stock · 72,600 shares Expires 2032-03-10 F3 · derivative.exercise_date: Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:03 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Tax withholdingCommon Stock | 1,989 | $1.82 | $3,619.98 |
DisclosureSEC source: 0001104659-22-033392 · tm229119-4_4seq1.xml · nonDerivative · entry 2 Korbel Gregory Alan · CIK 0001789032 · Director · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,852 F2 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 5,000 restricted stock units Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:03 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-033392 · tm229119-4_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · Director · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,841 F1 · shares: These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 5,333 shares on March 10, 2023, (ii) 5,333 shares on March 10, 2024 and (iii) 5,334 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 22:02 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Tax withholdingCommon Stock | 1,326 | $1.74 | $2,307.24 |
DisclosureSEC source: 0001104659-22-028761 · tm227953-3_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,841 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 3,333 restricted stock units. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Exercise / conversionStock Option (right to Buy) · Derivative | 27,500 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001104659-21-146396 · tm2134490-1_4seq1.xml · derivative · entry 3 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,335 Underlying: Common Stock · 27,500 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on February 26, 2017 and is fully exercisable. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | SaleCommon Stock | 27,500 | $3.96 | $108,900.00 |
DisclosureSEC source: 0001104659-21-146396 · tm2134490-1_4seq1.xml · nonDerivative · entry 2 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,167 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $4.12 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Exercise / conversionCommon Stock | 27,500 | $0.92 | $25,300.00 |
DisclosureSEC source: 0001104659-21-146396 · tm2134490-1_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:34 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Exercise / conversionStock Option (right to Buy) · Derivative | 2,255 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001104659-21-133785 · tm2131764-1_4seq1.xml · derivative · entry 4 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,835 Underlying: Common Stock · 2,255 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on February 26, 2017 and is fully exercisable. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:34 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Exercise / conversionStock Option (right to Buy) · Derivative | 25,245 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001104659-21-133785 · tm2131764-1_4seq1.xml · derivative · entry 3 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,245 shares Expires 2026-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 14, 2016 and is fully exercisable. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:34 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | SaleCommon Stock | 27,500 | $5.00 | $137,500.00 |
DisclosureSEC source: 0001104659-21-133785 · tm2131764-1_4seq1.xml · nonDerivative · entry 2 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,167 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.90 to $5.09 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:34 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Exercise / conversionCommon Stock | 27,500 | $0.92 | $25,300.00 |
DisclosureSEC source: 0001104659-21-133785 · tm2131764-1_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Exercise / conversionStock Option (right to Buy) · Derivative | 27,500 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001104659-21-123185 · tm2129205-1_4seq1.xml · derivative · entry 3 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,245 Underlying: Common Stock · 27,500 shares Expires 2026-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 14, 2016 and is fully exercisable. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | SaleCommon Stock | 27,500 | $4.89 | $134,475.00 |
DisclosureSEC source: 0001104659-21-123185 · tm2129205-1_4seq1.xml · nonDerivative · entry 2 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,167 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.80 to $5.06 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Exercise / conversionCommon Stock | 27,500 | $0.92 | $25,300.00 |
DisclosureSEC source: 0001104659-21-123185 · tm2129205-1_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Exercise / conversionStock Option (right to Buy) · Derivative | 27,500 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001104659-21-118363 · tm2127534-4_4seq1.xml · derivative · entry 4 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,745 Underlying: Common Stock · 27,500 shares Expires 2026-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on September 14, 2016 and is fully exercisable. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | SaleCommon Stock | 27,500 | $4.97 | $136,675.00 |
DisclosureSEC source: 0001104659-21-118363 · tm2127534-4_4seq1.xml · nonDerivative · entry 3 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,167 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $5.54 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Exercise / conversionCommon Stock | 27,500 | $0.92 | $25,300.00 |
DisclosureSEC source: 0001104659-21-118363 · tm2127534-4_4seq1.xml · nonDerivative · entry 2 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | SaleCommon Stock | 5,460 | $4.98 | $27,190.80 |
DisclosureSEC source: 0001104659-21-118363 · tm2127534-4_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,167 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.76 to $5.48 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Tax withholdingCommon Stock | 1,724 | $4.59 | $7,913.16 |
DisclosureSEC source: 0001104659-21-115547 · tm2127534-1_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,627 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 5,000 restricted stock units. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 21:02 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Tax withholdingCommon Stock | 1,149 | $3.98 | $4,573.02 |
DisclosureSEC source: 0001104659-21-110599 · tm2126037-3_4seq1.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,351 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 3,333 restricted stock units. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 22:30 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-21-000282 · form4.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 F1 · shares: These shares represent restricted stock units which were granted on March 10, 2021, and which will vest and be settled in common stock as follows: (i) 5,000 shares on September 10, 2021, (ii) 5,000 shares on March 10, 2022 and (iii) 5,000 shares on September 10, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 41,100 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001140361-21-006726 · form4.xml · derivative · entry 2 Korbel Gregory Alan · CIK 0001789032 · VP of Business Dev't 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,100 Underlying: Common Stock · 41,100 shares Expires 2031-02-25 F2 · derivative.exercise_date: Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-006726 · form4.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · VP of Business Dev't 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F1 · shares: These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 3,333 shares on August 25, 2021, (ii) 3,333 shares on February 25, 2022 and (iii) 3,334 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 12,800 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001104659-20-038881 · a4.xml · derivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · VP of Business Dev't 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,800 Underlying: Common Stock · 12,800 shares Expires 2030-03-24 F1 · derivative.exercise_date: Twenty-five percent of these options vest on March 24, 2021, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:21 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 64,322 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001140361-19-018077 · form4.xml · derivative · entry 2 Korbel Gregory Alan · CIK 0001789032 · VP of Business Dev't 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,322 Underlying: Common Stock · 64,322 shares Expires 2029-10-02 F1 · derivative.exercise_date: Twenty-five percent of these options vest on October 2, 2020, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:21 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 500 | $15.00 | $7,500.00 |
DisclosureSEC source: 0001140361-19-018077 · form4.xml · nonDerivative · entry 1 Korbel Gregory Alan · CIK 0001789032 · VP of Business Dev't 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.